Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Abstract

Gemcitabine-based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second-line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, allosteric non-competitive inhibitor of MEK1/MEK2. In this phase… (More)
DOI: 10.1111/cas.13438

Topics

6 Figures and Tables